Гиперфильтрация при артериальной гипертензии: распространенность, клиническое значение, пути коррекции
Диссертация
На основании анализа лабораторных исследований амбулаторных пациентов и больных, госпитализированных в течение 1 года в кардиологическое отделение ГКБ № 4, изучить встречаемость ГФ в популяции больных с АГ и оценить корреляционную связь ГФ с полом, возрастом, весом пациентов, а также рядом клинических и лабораторных параметров. Впервые проведена сравнительная оценка нефропротективного эффекта… Читать ещё >
Список литературы
- Арутюнов Г. П. «Патофизиологические процессы в почках у больных хронической сердечной недостаточностью». Журнал Сердечная недостаточность, том 9, номер 5 (49), 2008, стр. 234−250.
- Арутюнов Г. П., Чернявская Т. К., Лукичева Т. И. и др. Микроальбуминурия и пути ее медикаментозной коррекции // Клин, фармакол. и тер, — 1999.-№ 3.-С. 23−28.,
- Архипов В.В., Папаян А. В., Береснева Е. А. Маркеры функции почек и оценка прогрессирования почечной недостаточности. Терапевтический архив, 2004, № 4. С. 83−90.
- Арьев А. Л. Возможности использования субмаксимального нагрузочного теста для оценки функционального состояния почек в практике ВТЭ. Организационно-методические вопросы социально-трудовой реабилитации инвалидов. Сб. науч. тр. -Л.: 1987, с.45−50.
- Арьев А. Л., Тараненко Е. А., Чистякова Ю. Г. Патент «Способ диагностики функционального почечного резерва», Медицинская Академия последипломного образования Коноваловой И.Г.
- Белоусов Ю.Б. Поражение органов мишеней при артериальной гипертонии. Тер. арх. 1997- 69 (4): С. 12−15.
- Белоусов Ю.Б., Моисеев B.C., Лепахин В. К. Клиническая фармакология и фармакотерапия, Руководство для врачей, Универсум 1993 г.
- Бутрова С.А. Синдром инсулинорезистентности при абдоминальном ожирении. «Лечащий врач», № 7, стр. 32−36, 1999 г.
- Диденко В.А. Показатели инсулинового обмена у больных артериальной гипертонией. В кн.: Сборник тезисов. Жуковский: ЦПДС Единение 1999- 89−90
- Ю.Дмитрова Т. Б., Кобалава Ж. Д., Кардиоренальный синдром, Русский Медицинский Журнал, 2003 г, том 11, № 12, 699
- Зимин Ю.В. Происхождение, диагностическая концепция и клиническое значение синдрома инсулинорезистентности или метаболического синдромаХ. Кардиология. 1998- 6: 71−81.
- Ил Ларионова Т. С., Стуров Н. В., Чельцов В. В., Препараты, применяемые для лечения гипертонической болезни, РМЖ, 2007 г., том 15, № 28 21 242 130
- Карпов Ю.А. «Европейские рекомендации по артериальной гипертонии 2007 г.: блокаторы- ангиотензиновых рецепторов усиливают позиции», РМЖ, том 15, № 20, 2007
- Клинические практические рекомендации по Хроническому Заболеванию Почек: Оценка, Классификация и Стратификация, National Kidney Foundation K/DOQI, 2002.
- Кутырина И., Е. Краснова, Е. Федорова, В. Фомин, Поражение почек при ожирении: клинические, патогенетические и терапевтические аспекты. «Врач», № 6, 2005
- Кутырина И.М. Лечение артериальной гипертонии при хронических заболеваниях почек, РМЖ, 1997 г, том 5, № 23, стр. 7
- Моисеев В1С., Кобалава Ж. Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клин фармак тер 2002- 11(3): 16—8.
- Мухин Н., ' Л.Козловская, С. Моисеев и соавт. «Секреты метаболического синдрома», Клинический разбор в Клинике нефрологии, внутренних и профессиональных болезней им. Е. М. Тареева ММА им. И. М. Сеченова, журнал «Врач», № 4, 2005 г.
- Мухин Н.А. Снижение скорости клубочковой фильтрации — общепопуляционный маркер неблагоприятного прогноза Тер архив 2007- 6: 5—10.
- Мухин Н.А., Дедов И. И., Шестакова М. В. и др. Функциональные почечные резервы у больных сахарным диабетом // Терапевт, арх. — 1990. — № 2. — С. 107−110.
- Мухин Н.А., Моисеев B.C., Кобалава Ж. Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив 2004- 6: 39—46.
- Мухин Н.А., Фомин В. В., Моисеев С. В., Нанчикеева M.JL. Микроальбуминурия — универсальный маркер неблагоприятного прогноза ЖСН, март, т. 9 № 2 2008 г.
- Небиеридзе Д. В., Современные принципы контроля мягкой артериальной гипертонии, Кардиология СНГ, Том 4 2006, 240
- Подзолков В.И., Осадчий К. К., «Сердечно-сосудистый континуум: могут ли ингибиторы АПФ разорвать „порочный круг“?», РМЖ № 16, 2008
- Поливода С.Н., Черепок А. А., Кулинич P.J1. Оценка функционального состояния почек как предиктора эффективности антигипертензивной терапии у больных с гипертонической болезнью // Укр. кардюл. журн. — 2005.-№ 3.-С. 90−95.
- Ратнер М.Я. Оценка почечных функций и классификация их расстройств при заболеваниях почек В кн.: Ратнер МЯ, Серов В. В., Томилина НА Ренальные дисфункции. М: Медицина 1977: 32−54
- Рогов В.А., Кутырина И. М., Тареева И. Е. и др. Функциональный резерв почек при нефротическом синдроме // Тер. архив. 1990. — N6. — С.55−58.
- Сагинова Е. А., Федорова Е. Ю., Фомин В. В Формирование поражения почек у больных. Терапевтический архив том 78 № 5 20 066 стр. 36−41
- Смирнов А.В., Добронравов В. А., Каюков И. Г. Проблема хронической болезни почек в современной медицине. Артер гиперт 2006- 12(3)
- Тареева И.Е., А.Ю. Николаев, H. J1. Лифшиц. Диагностика и консервативное лечение хронической почечной недостаточности. Методич. рекомендации для врачей. М., 1993.
- Томилина Н.А. Применение иАПФ в нефрологической клинике (Методические рекомендации № 17, Москва, 2000 г.),
- Томилина Н.А., Бигбов Б. Т. Эпидемиология хронической почечной недостаточности и новые подходы к классификации и оценке тяжести хронических прогрессирующих заболевания почек. Тер архив 2005- 6: 87—92.
- Чазова И.Е., Л.Г.Ратова и соавт. Нефропротекция в лечении больных артериальной гипертонией (результаты исследования ИРИС) Том 07/N 1/2005 Нефрология
- Amiel С., Blanchet F., Friedlander G., Nitenberg A. Renal functional reserve // Nephrol. Dial. Transplant. 1990. — V.5. — P.763−770.
- Asselbergs F.W., Diercks G.F.H., Hillege H.L. et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004- 110: 2809 2816
- Baud L., Fouqueray В., Amrani P.C. Tumor necrosis factor alpha and mesangial cells // Kidney Int. 1992- 41: 600−603.
- Beluwkes R. III. The vascular organization of the kidney. Annu Rev Physiol 1980,42, 531
- Bigazzi R., Bianchi S., Baldari D., Campese V.M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens. 1998−16: 1325 1333
- Black MJ, Briscoe ТА, Dunstan HJ, Bertram JF, Johnston CI: Effect of angiotensin-converting enzyme inhibition on renal filtration surface area in hypertensive rats. Kidney Int 2001−60:1837−1843.
- Borch-Johnsen K., Feldt-Rasmussen В., Strandgaard S. et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler. Thomb. Vase. Biol. 1999- 19: 1992 1997
- Bosch J.P., Lew S., Glabman S., Lauer A. Renal hemodynamic changes in humans: response to protein loading in normal and diseased kidneys // Am.J.Med. 1986. — V.81. — P.809−816.
- Bosch J.P., Saccagi A., Lauer A. et al. Renal functional reserve in humans. Effect of protein intake on glomerular rate// Am. J. Med., 1983, v. 75, p. 943 -950
- Boucher J et al. (2005) Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 146: 1764−1771
- Brenner B.M., Mackenzie H.S. Nephron mass as a risk factor for progression of renal disease // Kidney Intern. 1997- 52(Suppl 63): P. 124−127.
- Brenner BM, Cooper ME, de Zeeuw D et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001−345:861−869.
- Brosius FC III, Hostetter TH, Kelepouris E. et al. AHA Science advisory on detection of kidney disease in patients with or at increased risk of cardiovascular disease. Circulation 2006- 114: 1083—7.
- Butler J., Forman D.E., Abraham W.T. et al. Relationship between HF treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004, 147, 331−338
- Cassellas D., Moore L.G. Autoregulation and tubuloglomerular feedback in juxtamedullary glomerular arterioles. Am J Physiol 1990, 258, PF660-F669
- Cerasola G., Cottone S., Mule G. et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J. Hypertens. 1996- 14(7): 915−920,
- Chagnac A et al. (2003) The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14: 1480−1486
- Chagnac Avry, Herman Michal et al. P-333: Effect of obesity-induced hyperfiltration on renal peritubular capillary oncotic pressure Am J Hypertens (2005) 18, 127A-127A- doi:10.1016/j.amjhyper.2005.03.351
- Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004- 140: 167−176.
- Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003- 289: 2560−2572.
- Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine Nephron 1976- 16: 31−41.
- Cohn SH, Abesemis C, Zanzi I, Aloia JF, Yasumura S, Ellis KJ. Body elemental composition: comparison between black and white adults. Am J Physiol. 1977−232:E419−22.
- Current Opinion in Nephrology & Hypertension. Obesity, proteinuria and progression of renal failure. Pharmacology and therapeutics. 15(5):481−486, September 2006.
- Dahlquist G, Aperia A, Broberger О et al. Renal function in relation to metabolic control in children with diabetes of different duration. ActaPaediatr Scand 1983- 72: 903−909.
- De Ferranti SD et al. (2004) Prevalence of the metabolic syndrome in American adolescents: findings from the Third National Health and Nutrition Examination Survey. Circulation 110: 2494−2497
- De Jong P.E., Brenner B.M. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004- 66: 2109−2118,
- De Jong PE, Hillege HL, Pinto-Sietsma SJ, De Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? NephroLDial Transplant 2003- 18: 10−13.
- Deinum J, Derkx FH: Cystatin for estimation of glomerular filtration rate? Lancet 356:1624−1625, 2000
- Delles C, Jacobi J, John S, Fleischmann I, Schmieder RE: Effects of enalapril and eprosartan alone or in combination on the renal vascular nitric oxide system in human essential hypertension. Kidney Int 2002−61:1462−1468.
- Delles C., Klingbeil Arnfried U., Schneider Markus P. et al. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension Am J Hypertens (2003) 16, 1030−1035
- Delles С., Schmieder R.E. Renal endothelial effects of antihypertensive therapy. Curr. Opin. Nephrol. Hypertens. 2004- 13: 489 493
- Dengel D.R., Glodberg A.P., Mayuga R.S. et al. Insulin resistance, elevated glomerular filtration fraction and renal injury // Hypertension. 1996- 28:127 132
- Dharnidharka VR, Kwon C, Stevens G. Serum cystatin С is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002- 40: 221—6.
- Dries D.L., Exner D.V., Domanski M.J. et al. The prognostic implication of renal insufficiency in asymptomatic and symptomatic patients with. left ventricular systolic dysfunction. JACC 2000, 35, 3, 681−689
- Dzhusipov A.K., Kistauova B.Z., Ligay Z.N., Dzhunusbekova G.A. Comparative estimation of eprosartan and fosinopril influence on renal hemodynamics in arterial hypertension patients. CIS Cardiology, 2006. vol. 4. Л о 2
- Effects of diet and antihypertensive therapy on creatinine clearance and serum creatinine concentration in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996−7:556−65.
- Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996−27:652−63.
- Engeli S., Negel R., Sharma A.M. Pathophysiology of the adipose tissue renin-angiotensin system // Hypertension. -2000- 35: 1270- 1276.
- ESH-ESC Guidelines Committee. ESH-ESC guidelines for the management of arterial hypertension. J. Hypertens. 2003- 21: 1011 1053, et al.
- Fenoy F.J., Quesada Т., Garsi-Salom M. et al. Hemodynamic effects of chronic infusion of ANP in renal hypertensive rats. Am J Physiol 1989, 256, H1393−1398
- Festa A, D’Agostino R Jr, Howard G, et al: Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102:42−47, 2000
- Fliser D, Dikow R, Demukaj S, Ritz E: Opposing effect of angiotensin II on muscle and on renal blood flow under euglycemic conditions. J Am Soc Nephrol 11: 2001 -2006, 2000
- Fliser D, Pacini G, Engelleiter R et al. Insulin resistance and hyperinsulinemia are already present in patient with incipient renal disease. Kidney Int 1998- 53: 1343−1347
- Fliser D., Wagner K. et al., «Chronic Angiotensin II Receptor Blockade Reduces (Intra)Renal Vascular Resistance in Patients with Type 2 Diabetes», J Am Soc Nephrol 16: 1135−1140, 2005
- Ford ES et al. (2004) Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 27: 2444−2449
- Fried L.F., Shlipak M.G., Crump G. et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. JACC 2003, 41, 1364−1372
- Foster MC et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Diseases, 2008, 52: 3918
- Gabbai F.B. Renal reserve in patients with high blood pressure // Semin. Nephrol. 1995. — V.15. — P.482−487.
- Gabbai F.B. The glomerular capillary membrane a passive or active structure. J Lab Clin Med 1995, 125, 419−420
- Gaillard C.A., Mizelle H.L., Mantani J.P. et al. ANF and blood pressure control: role of sodium and aldosterone. Am J Physiol 1990, 259, R973−980)
- Gault MH, Longerich LL, Harnett JD, Wesolowski C: Predicting glomerular function from adjusted serum creatinine. Nephron 62:249−256, 1992
- Gerber L.M., Shmukler C., Alderman M.H. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch. Intern. Med. 1992- 152: 373 -377
- Gottlieb S.S., Abraham W., Butler J. et al. The prognostic importance of different definitions of worsening renal function in congestive HF. J Card Fail 2002, 8, 136−141
- Graninger M., Reiter R., Drucker C. et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J. Cardiovasc. Pharmacol. 2004- 44: 335 -339
- Guidelines Committee. 2003 European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003- 21: 1011−1053.
- Gussekloo J, Schaap MC, Frolich M, et ah C-reactive protein is strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vase Biol 20:1047−1051, 2000
- Hall JE et al. (2002) Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 324: 127−137
- Harsha DW, Frerichs RR, Berenson GS. Densitometry and anthropometry of black and white children. Hum Biol. 1978−50:261−80.
- Hellerstein S, Berenbom M, Alon US, Warady BA: Creatinine clearance following cimetidine for estimation of glomerular filtration rate. Pediatr Nephrol 12:49−54, 1998
- Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983−37:478−94.
- Hillege H.L., Janssen W.M., Bak A.A. et al. Microalbuminuria is common, also in a non-diabetic, non-hypertensive population, and anindependent indicator of a cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 2001- 249: 519−526
- Horng H Chen- ShuChong Pan- John С Burnett- Robert D Simari, A Novel Aquaretic and Glomerular Filtration Rate Enhancing Peptide Without Vascular Vasodilatory Actions in Experimental CHF. Circulation. 2007−116:II61
- Hornig B. Effects of AT,-receptor blockade on endothelial dysfunction// 2nd Intern. Forum on angiotenzin II receptor antagonism. — Monte-Carlo, 2001- absti p. 18−19.
- Hostetter Т.Н. Renal hemodynamic response to a meat meal in humans // Kidney Int. -1984. V.25. — P. 168.
- Hostetter T.M., Olson J.L., Rennke H.G. et al. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation // Am. J. Physiol. -1981. V.9. -P.85−93.
- Hotamisligil GS et al. (1995) Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409−2415
- Hsu C, McCulloch CE, Iribarran С et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006- 144: 21−28.
- Hunsicker LG, Adler S, Cagguila A et al Predictors of the progressive association of cardiovascular risk factors with incident proteinuria. Arch Intern Med 2005- 165: 2299−2304.
- Iseki K, Ikemiya Y, Kinjo К et al. Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004- 65: 1870−1876.
- Jamie Traynor, Robert Mactier, Colin G Geddes, Jonathan G Fox, How to evaluate renal function in clinical practice? BMJ.
- Jee SH, Bouware LB, Guallar E et al. Direct, progressive association of cardiovascular risk factors with incident proteinuria. Arch Intern Med 2005- 165: 2299−2304.
- Jensen JS, Feldt-Rasmussen B, Strandgard S et al. Arterial hypertension, microalbuminuria, and ischemic heart disease. Hypertension 2000- 35:898 903.
- Karalliedde J, Viberti G. Microalbuminuria and cardiovascular risk. Am J Hypertens 2004- 17: 986−993
- Kern PA, Ranganathan S, Li C, et al: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280: E745-E751, 2001
- Kielstein JT, Becker B, Graf S et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003- 42: 62−66.
- Kjoller-Hansen L, Steffensen R, Grande P. The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J Am Coll Cardiol. 2000- 35: 881−888.
- Klahr S, Levey AS, Beck GJ, Caggiula A Wet al. The effects of dietary protein restriction and blood-pressure control on the progression of renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994−330:877−84.
- Kohan D.E. Endothelins in the normal and diseased kidney // Am. J. Kidney Dis. 1996- 1: 2−26.
- Kriz W., Bankir L. A standard nomenclature for structures of kidney. Am J Physiol 1988, 254, F1-F8.
- Krumholz H.M., Chen Y.T., Vaccarino V. et al. Correlates and impact on outcomes of worsening renal function in patients > 65 years of age with HP. Am J Card 2000, 85, 1110−1113
- Kubo S, Nishioka A, Nishimura H, et al. Effects of captopril on arterial and venous pressure, renal function, and humoral factors in severe chronic congestive heart failure. Clin Pharmacol Ther. 1984- 36: 456—463.
- Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk of chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005- 16: 2134−2140.
- Larry A. Slomowitz, Orjan W. Peterson, Scott C. Thomson. Baylor Converting Enzyme Inhibition and the Glomerular Hemodynamic Response to Glycine in Diabetic Rats J Am Soc Nephrol 10:1447−1454, 1999
- Lekatsas I., Koulouris S., Triantafyllou K. et al. Prognostic significance of microalbuminuria in non-diabetic patients with acute myocardial infarction. Int. J. Cardiol. 2006- 106 (2): 218−223
- Leoncini G, Sacchi G, Ravera M et al. Microalbuminuria is an integrated marker of subclinical organ damage in primary hypertension. J Hum Hypertens 2002- 16: 399−404.
- Levey AS, Adler S, Caggiula AW, England BK et al. Effects of dietary protein restriction on the progression of advanced renal disease in the Modification of Diet in Renal Disease Study. Am J Kidney Dis. 1996−27:652−63.
- Lindheimer M.D., Lalone R.C., Levinsky N.G. Evidence that an acute increase in glomerular filtration has little effect in the dog unless extracellular volume in expanded // J. Clin. Invest. 1967. — V.46. — P.256−265.
- Locatelli F, Pozzoni P, Del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol 2006- 17: S81-S85.
- Luca De Nicola, Roland С Blantz and Francis В Gabbai, Renal functional reserve in treated and untreated hypertensive rats, Kidney International (1991) 40, 406−412
- Maddox D.A., Brenner B.M. Glomerular ultrafiltration. In Brenner B. Mi «The Kidney». W.B. Saunders CO 1991, chapter 6
- Makino H., Hironaka K., Shikata K. et al. Mesangial matrix act a mesangial channels to the juxtaglomerular zone. Nephron 1994, 66, 181−188
- Mendall MA, Strachan DP, Butland BK, et al: C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J21:1584−1590- 2000
- Meyrier A, Simon P. Nephroangiosclerosis and hypertension: things are not as simple as you might think. Nephrol Dial Transplant 1996- 11: 2116— 2120.
- Mimran A. Renal function in hypertension // Amer. J. Med. 1988. -Vol. 84 (Suppl. IB). — P. 69−75.
- Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984- 311: 89−93.
- Morel F., Doucet A. Functional segmentation of the nephron. In Seldin D.W. «The kidney», chapter 31
- O’Meara E., Chong K.S., Gardner R.S. et al. The modification of Diet in Renal Disease (MDRD) equations provide valid estimation of GFR in patients with advanced HF. Eur J Heart Fail 2006, 8 63−67
- Ochodnicky P., Henning R.H., van Dokkum R.P., de Zeeuw D. Microalbuminuria and endothelial dysfunction: emerging targets for primary prevention of end-organ damage. Cardiovasc. Pharmacol. 2006- 47 (Suppl. 2): S151 -S162
- P Palatini, P Mormino, F Dorigatti et al. on behalf of the HARVEST Study Group, Kidney International (2006) 70, 578−584.
- Parving HH, Lehnert H, Bro’chner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001- 345:870−878.
- Pedrinelli R., Giampietro O., Carmassi F. et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994- 344: 14- 18
- Peterson JC, Adler S, Burkhart JM, Greene T, Hebert LA, King AJ, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995−123:754−62.
- Pichet R., Cantin M., Thibault G. et al. Hemodynamic and renal responses in physiological levels of ANF in conscious dog. Hypertens 1989, 14, 104−110
- Pitt B. Potential role of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995−16:49−54
- Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Circulation 2006−113:898−918.
- Praga M. Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy. Nephrol Dial Transplant 2005- 20: 2594−2597.
- Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel MJ, Galanski M, Koch KM, Haller H: Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 344: 410 —417, 2001
- Redon J, Rovira E, Miralles A et al. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002- 39: 794−798.
- Redon J, Ruilope LM. Microalbuminuria as an intermediate endpoint in essential hypertension: evidence is coming. J Hypertens 2004- 22: 1679−1681.
- Reilly R.F., Ellison D.H. Mammalian distal tubule: physiology, pathophysiology and molecular anatomy. Physiol Rev 2000, 80, 277−313
- Resnick L.M. Ionic basis of hypertension, insulin resistance, vascular disease and related disorders. Am. J. Hypertens. 1993- 6: S123-S134
- Ridker PM: High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103:1813−1818, 2001
- Ruilope L.M., Van Veldhuisen D.J., Ritz E. et al. Renal function: the Cinderella of cardiovascular risk profile. JACC 2001, 38, 1782−1787
- Ruilope LM, Campo C, Rodriguez-Artalejо F, Lahera V, Garcia-Robles R, Rodicio JL. Blood pressure and renal function: therapeutic implications. J Hypertens 1996- 14: 1259−1263.
- Rule Andrew D., Cosio Fernando G., The New Mayo Clinic Equation for Estimating Glomerular Filtration Rate, Annals of Internal Medicine, 2005, Volume 142, Issue 8, Page 681
- Rule Andrew D.- Larson Timothy S. et al. Using Serum Creatinine To Estimate Glomerular Filtration Rate: Accuracy in Good Health and in Chronic Kidney Disease. © 2004 American College of Physicians 929
- Sachman H., Tran-Van Т., Tack I. et al. Contrasting renal functional reserve in very long-term type I diabetic patients with and without nephropathy // Diabetologia. 2000. — V.43. — P.227−230.
- Sands J.M., Kokko J.P., Jacobson H.R. Intrarenal heterogeneity vascular and tubular. In Seldin D.W. «The kidney», chapter 32
- Selcurt E.E. The relation of renal blood flow to effective arterial pressure in the intact kidney of the dog. Am J Physiol 1946, 147, P537-P549
- Seldin D.W., Giebisch G. The kidney: Physiology and1 Pathophysiology. 2nd ed. NY Raven Press 1992
- Seliger SL, DeFilippi C. Role of Cystatin С as a Marker of Renal Function and Cardiovascular Risk Medscape 26 Oct 2006. www. medscape.com
- Semplicini A, Ceolotto G, Sartori M et al. Regulation of glomerular transport and filtration in essential hypertension: role of abnormal Na atrial natriuretic peptide. J Nephrol 2002- 15: 489−496.
- Shankar S.S., Steinberg H.O. Obesity and endothelial dysfunction. Semin. Vase. Med. 2005- 5: 56 64
- Short-term effects of protein intake, blood pressure, and antihypertensive therapy on glomerular filtration rate in the Modification of Diet in Renal Disease Study. J Am Soc Nephrol. 1996−7:2097−109.
- Smilde T.M., Hillege H.L., Navis G. et al. Formulas estimating renal function give imprecise estimates in HF. JACC, 2005, 45, 172A-177A
- Smith G.L., Vaccarino V., Kosiborod M. et al. Wosening renal function what is a clinically meaningful change in creatinine during hospitalization with HF. J Card Fail 2003, 9, 13−25
- Sowers J.R., Standley P.R., Ram J.L. et al. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in pathogenesis of hypertension and atherosclerosis. Am. J. Hypertens. 1993- 6: S260-S270.
- Sowers JR (2007) Metabolic risk factors and renal disease. Kidney Int 71: 719−720
- Steinke JM, Sinaiko AR, Kramer MS et al. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005- 54: 2164−2171.
- Stevens AL, Coresh J, Greene T, Levey AS. Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate. N Engl J Med 2006- 354: 2473—83.
- Stuveling Erik M, Hillege Hans L, Bakker Stephan JL, et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population Kidney International (2003) 63, 654−661
- Suzuki К., Tatara К. Clustered Features of the Metabolic Syndrome and the Risk for Increased Aortic Pulse Wave Velocity in Middle-aged Japanese Men, Angiology, Vol. 54, No. 5, 551−559 (2003)
- Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 2000−57:1803−1817.
- Tanaka H, Shiohira Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006- 69: 369−374.
- Taskinen M.R. Strategies for the diagnosis of metabolic syndrome. Current Opinion in Lipidology. 1993- 4: 434−443.
- The ESH ESC Task Force. 2007 Guidelines for the Management of the Arterial Hypertension. J. Hypertens. 2007- 25: 1105 — 1187
- The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction and stroke in high-risk patients. New Engl J Med 2000−342: 145−153.
- The HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000- 355: 253 259 ,
- Tomaszewski M et al. (2007) Glomerular hyperfiltration: a new marker of metabolic risk. Kidney Int 71: 816−821
- Tommaso Bochicchio, Guadalupe Sandoval et al. Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives Kidney International (1990) 38, 873−879- doi:10.1038/ki.l990.285
- Walser M: Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 32:23−31, 1998
- Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int Suppl 1992- 36: S33−37
- Whaley-Connell A, Sowers K, Sowers JR. Hypertension and cardiovascular disease. In: Cortes P, Mogensen CE (eds). Contemporary Diabetes: The Diabetic Kidney. Humana Press: Totowa, New Jersey, 2006, pp 497−511
- Whaley-Connell AT, Chowdhury NA, Hay den MR et al. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol 2006- 291: F1308-F1314
- Windhager E.E. Renal Physiology In Handbook of Physiology, Section 8. NY. Oxford University Press 1992
- Wolf G, Chen S, Han DC et al. Leptin and renal disease. Am J Kidney Dis 2002- 39: 1−11.
- Wu Y et al. (2006) Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology 147: 44—50
- Xue J. L., Ma J. Z., Louis T. A. andCollins A. J. 2001. Forecast of the Number of Patients with End-Stage Renal Disease in the United States to the Year 2010 Journal of the American Society of Nephrology 12: 2753 58
- Yusuf S, Sleight P, Pogue J, et al, for the Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000- 342: 145−153.
- Yuyun M.F., Khaw K.T., Luben R. et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am. J. Epidemiol. 2004- 159: 284 293
- Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundamental&Clinical Pharmacology 2007- 21: 181−190.
- Zhong-Gao Xu, MD, PhD- Linda Lanting, BS- Nosratola D. Vaziri, MD- et. al. Upregulation of Angiotensin II Type 1 Receptor, Inflammatory Mediators, and Enzymes of Arachidonate Metabolism in Obese Zucker Rat Kidney Circulation. 2005- 111:1962−1969.
- Zitta S., Stoschitzky K., Zweiker R. et al. Dynamic renal function testing by compartmental analysis: assessment of renal functional reserve in essential hypertension // Nephrol. Dial. Transplant. 2000. — Vol. 15. — № 8. — P. 11 621 169.151